Related Experiment Video

Updated: Jul 11, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Combating KRASG12C Inhibitor Resistance

    Cancer Discovery
    |November 3, 2023
    PubMed

    Insights

    Combining KRASG12C inhibitors with other therapies improves efficacy in colorectal cancer. Adding panitumumab to sotorasib shows promise, and SHP2 blockade may reverse resistance.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Clinical Trials

    Background:

    • KRAS G12C mutations drive tumor growth and are targeted by specific inhibitors.
    • Cancer cells develop resistance to KRAS G12C inhibitors, limiting treatment effectiveness.
    • Combination strategies are essential to overcome resistance and enhance therapeutic outcomes.

    Purpose of the Study:

    • To evaluate combination therapies for KRAS G12C-mutated colorectal cancer.
    • To assess the efficacy of adding panitumumab (EGFR inhibitor) to sotorasib (KRAS G12C inhibitor).
    • To investigate the potential of SHP2 blockade in reversing acquired resistance to KRAS G12C inhibitors.

    Main Methods:

    • Phase III CodeBreaK 300 trial comparing sotorasib plus panitumumab versus standard care.
    • Analysis of outcomes in patients with chemorefractory KRAS G12C colorectal cancer.
    • Preliminary Phase I data evaluating joint SHP2 blockade for acquired resistance.

    Main Results:

    • Sotorasib plus panitumumab demonstrated superior outcomes compared to standard care in the trial.
    • Preliminary data suggest SHP2 blockade has activity in overcoming acquired resistance mechanisms.
    • Combination strategies show potential in managing advanced KRAS G12C colorectal cancer.

    Conclusions:

    • Adding panitumumab to sotorasib is a promising strategy for chemorefractory KRAS G12C colorectal cancer.
    • SHP2 blockade represents a potential therapeutic avenue for overcoming acquired resistance.
    • Further research into combination therapies is crucial for improving patient outcomes in KRAS G12C-driven cancers.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.9K
    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    14.9K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.3K
    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    6.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.7K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.8K